Was the ResMed (RMD) CEO’s share sale under a Rule 10b5-1 plan?

Yes. The filing states the transaction was conducted under a Rule 10b5-1 trading plan adopted on October 31, 2024. Such pre-arranged plans automate trades over time, reducing the significance of day-to-day market timing for interpreting insider activity.

ResMed (NYSE: RMD) CEO sells 4,991 shares under 10b5-1 plan

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

ResMed Inc.’s Chairman and CEO Michael J. Farrell reported a same-day option exercise and share sale in ResMed common stock. He exercised options to acquire 4,991 shares at $146.34 per share, then sold 4,991 shares in an open-market transaction at a weighted average price of $207.8206 per share.

After the sale, Farrell directly holds 466,223 ResMed shares and indirectly holds 2,090 shares through the Lisette and Michael Farrell Family Trust. The transactions were conducted on May 7, 2026 under a pre-arranged Rule 10b5-1 trading plan adopted on October 31, 2024, indicating a scheduled, routine disposition rather than ad hoc trading.

Insider Trade Summary 10b5-1

Net Seller: 4,991 shares ($1,037,233)

Net Sell 4 txns

Insider Farrell Michael J.

Role Chairman and CEO

Sold 4,991 shs ($1.04M)

Type	Security	Shares	Price	Value
Exercise	ResMed Common Stock Options	4,991	$0.00	--
Exercise	ResMed Common Stock	4,991	$146.34	$730K
Sale	ResMed Common Stock	4,991	$207.8206	$1.04M
holding	ResMed Common Stock	--	--	--

Holdings After Transaction: ResMed Common Stock Options — 29,948 shares (Direct, null); ResMed Common Stock — 471,214 shares (Direct, null); ResMed Common Stock — 2,090 shares (Indirect, Lisette and Michael Farrell Family Trust)

Footnotes (1)

The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. This transaction was executed in multiple trades at prices ranging from $206.45 - $210.47. The price reported above reflects the weighted average sale price. Represents date options first become exercisable. Options vest 1/3 per year.

Key Figures

Shares sold: 4,991 shares Sale price (weighted average): $207.8206 per share Exercise price: $146.34 per share +5 more

8 metrics

Shares sold 4,991 shares Open-market sale of ResMed Common Stock on May 7, 2026

Sale price (weighted average) $207.8206 per share ResMed Common Stock sale; trades ranged $206.45–$210.47

Exercise price $146.34 per share Option exercise for 4,991 ResMed shares

Direct holdings after transaction 466,223 shares ResMed Common Stock directly owned by Michael Farrell post-trade

Indirect holdings after transaction 2,090 shares Held via Lisette and Michael Farrell Family Trust

Remaining options 29,948 options ResMed Common Stock Options following 4,991-option exercise

Option expiration date November 21, 2026 Expiration for exercised ResMed Common Stock Options grant

10b5-1 adoption date October 31, 2024 Date CEO’s Rule 10b5-1 trading plan was adopted

Key Terms

Rule 10b5-1 plan, open-market sale, derivative exercise/conversion, ResMed Common Stock Options, +1 more

5 terms

Rule 10b5-1 plan regulatory

"The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024."

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

derivative exercise/conversion financial

"transaction_action: derivative exercise/conversion"

ResMed Common Stock Options financial

"security_title: ResMed Common Stock Options"

weighted average sale price financial

"The price reported above reflects the weighted average sale price."

Form 4 Insider Transactions: What Each Field Means →

05/11/2026 - 07:33 AM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Farrell Michael J.

(Last)

(First)

(Middle)

RESMED INC.

9001 SPECTRUM CENTER BLVD

(Street)

SAN DIEGO

CALIFORNIA

92123

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
RESMED INC [ RMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chairman and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
ResMed Common Stock	05/07/2026		M⁽¹⁾		4,991	A	$146.34	471,214	D
ResMed Common Stock	05/07/2026		S⁽¹⁾		4,991	D	$207.8206⁽²⁾	466,223	D
ResMed Common Stock								2,090	I	Lisette and Michael Farrell Family Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
ResMed Common Stock Options	$146.34	05/07/2026		M⁽¹⁾			4,991	11/11/2020⁽³⁾	11/21/2026	ResMed Common Stock	4,991	$0	29,948	D

Explanation of Responses:

1. The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024.

2. This transaction was executed in multiple trades at prices ranging from $206.45 - $210.47. The price reported above reflects the weighted average sale price.

3. Represents date options first become exercisable. Options vest 1/3 per year.

	/s/ Michael J. Farrell, Chairman and CEO	05/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did ResMed (RMD) CEO Michael Farrell report?

Michael Farrell exercised options for 4,991 ResMed shares at $146.34 and sold 4,991 shares at a weighted average of $207.8206 on May 7, 2026. These filings reflect a routine exercise-and-sell pattern common in executive compensation.

How many ResMed (RMD) shares does Michael Farrell hold after this Form 4?

After the reported transactions, Michael Farrell directly holds 466,223 ResMed common shares and indirectly holds 2,090 shares via the Lisette and Michael Farrell Family Trust. These holdings show he retains a substantial equity stake following the relatively small 4,991-share sale.

What prices were involved in Michael Farrell’s ResMed (RMD) Form 4 trades?

The option exercise occurred at an exercise price of $146.34 per ResMed share. The subsequent open-market sale of 4,991 shares reported a weighted average sale price of $207.8206, with individual trades executed between $206.45 and $210.47 during the transaction window.

What happened to Michael Farrell’s ResMed (RMD) stock options in this filing?

Farrell exercised 4,991 ResMed common stock options, reducing his remaining option position to 29,948 options. The exercised options had a $146.34 exercise price, first became exercisable on November 11, 2020, and were scheduled to expire on November 21, 2026 if unexercised.

How large is the ResMed (RMD) CEO’s reported sale relative to his holdings?

The filing shows a sale of 4,991 shares against post-transaction direct holdings of 466,223 shares. This indicates the disposition represents only a small fraction of his overall direct ownership, consistent with a routine liquidity event rather than a major position change.